New drugs and targets in haematological malignancies

Mutant-specific kinase inhibitors and TAT highlights

Drugging the cancer genome to overcome drug resistance

ecancermedicalscience editor's choice for February 2015

Effectiveness of adjuvant chemotherapy on patients with bladder cancer

ASCO GU 2015 news roundup

Taxane response in prostate cancer may not be influenced by androgen receptor variations

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma